St. Michael's FinancialJul 15, 2025

🔬 Biotech may have stumbled in FY25—but opportunity is building for FY26.

HB Biotechnology posted 23% outperformance in one of the toughest years for the sector. At St. Michaels Financial Services, we explore why strong fundamentals, thoughtful diversification, and regulatory shifts could drive a biotech rebound.

https://medium.com/@st.michaels.financial.serivces/biotechs-underrated-upside-positioning-for-opportunity-in-fy26-120e7ed2b432

#Biotech #Investing #FinancialStrategy #Markets #WealthManagement #StMichaelsFinancial #HealthcareEquities

Biotech’s Underrated Upside: Positioning for Opportunity in FY26

FY25 was no easy ride for healthcare and biotech investors. While global equity markets, including the ASX200, soared to record highs in early 2025, the biotech sector posted some of its weakest…

Medium
St. Michael's FinancialJul 15, 2025

📊 ASX200 hits a record high as Wall Street momentum lifts Australian markets.

Led by gains in tech and healthcare, the local index closed at a fresh peak despite mixed signals from China’s economy. At St. Michaels Financial Services, we break down what’s driving the rally—and what investors should watch next.

https://medium.com/@st.michaels.financial.serivces/asx200-hits-new-high-as-wall-street-momentum-carries-over-519830a58ee3

#Finance #ASX200 #Investment #WealthManagement #MarketNews #StMichaelsFinancial #AustralianMarkets

ASX200 Hits New High as Wall Street Momentum Carries Over

Australian shares surged to new heights on Tuesday, with the ASX200 closing at a fresh record as optimism from Wall Street buoyed local sentiment. Technology and healthcare stocks were standout…

Medium